المؤلفون: Pires da Silva I; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Faculty of Medicine & Health, The University of Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, NSW, Australia; Crown Princess Mary Cancer Centre Westmead, Blacktown Hospital, Sydney, Australia. Electronic address: ines.silva@melanoma.org.au., Li I; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia., Ugurel S; Department of Dermatology, University Hospital Essen, and German Cancer Consortium (DKTK) partner site Essen/Düsseldorf, Essen, Germany., Serra-Bellver P; The Christie NHS Foundation Trust, Manchester, UK., Andhale A; The Christie NHS Foundation Trust, Manchester, UK., Burnette H; Vanderbilt University Medical Center, Nashville, TN, United States., Aya F; Department of Medical Oncology, IDIBAPS, Hospital Clínic, Barcelona, Spain., Conway JW; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Faculty of Medicine & Health, The University of Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, NSW, Australia., Braden J; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Faculty of Medicine & Health, The University of Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, NSW, Australia., Carlino MS; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Crown Princess Mary Cancer Centre Westmead, Blacktown Hospital, Sydney, Australia., Menzies AM; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Faculty of Medicine & Health, The University of Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, Australia., Weichenthal M; University Skin Cancer Center Kiel, University Hospital of Schleswig-Holstein, Kiel, Germany., Mohr P; Elbe-Klinikum Buxtehude, Buxtehude, Germany., Gutzmer R; Ruhr University Bochum Campus Minden, Minden, Germany., Arance AM; Department of Medical Oncology, IDIBAPS, Hospital Clínic, Barcelona, Spain., Johnson DB; Vanderbilt University Medical Center, Nashville, TN, United States., Lorigan P; The Christie NHS Foundation Trust, Manchester, UK., Schadendorf D; Department of Dermatology, University Hospital Essen, and German Cancer Consortium (DKTK) partner site Essen/Düsseldorf, Essen, Germany; Westdeutsches Tumorzentrum (WTZ) & National Center for Tumor Diseases (NCT-West), Campus Essen & University Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany., Lo SN; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Faculty of Medicine & Health, The University of Sydney, NSW, Australia., Long GV; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Faculty of Medicine & Health, The University of Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, Australia. Electronic address: ines.silva@melanoma.org.au.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Jul; Vol. 205, pp. 114101. Date of Electronic Publication: 2024 May 07.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Melanoma*/drug therapy , Melanoma*/secondary , Melanoma*/mortality , Liver Neoplasms*/secondary , Liver Neoplasms*/drug therapy , Liver Neoplasms*/mortality , CTLA-4 Antigen*/antagonists & inhibitors , Programmed Cell Death 1 Receptor*/antagonists & inhibitors , Immune Checkpoint Inhibitors*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Male ; Retrospective Studies ; Female ; Middle Aged ; Aged ; Adult ; Aged, 80 and over ; Progression-Free Survival ; Skin Neoplasms/drug therapy ; Skin Neoplasms/pathology ; Skin Neoplasms/mortality

المؤلفون: Nahar KJ; Melanoma Institute Australia.; Faculty of Medicine and Health.; Charles Perkins Centre, and., Marsh-Wakefield F; Faculty of Medicine and Health.; Charles Perkins Centre, and.; Centenary Institute, The University of Sydney, Sydney, New South Wales, Australia., Rawson RV; Melanoma Institute Australia.; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia., Gide TN; Melanoma Institute Australia.; Faculty of Medicine and Health.; Charles Perkins Centre, and., Ferguson AL; Faculty of Medicine and Health.; Charles Perkins Centre, and.; Centenary Institute, The University of Sydney, Sydney, New South Wales, Australia., Allen R; Faculty of Medicine and Health.; Charles Perkins Centre, and., Quek C; Melanoma Institute Australia.; Faculty of Medicine and Health.; Charles Perkins Centre, and., da Silva IP; Melanoma Institute Australia.; Faculty of Medicine and Health.; Charles Perkins Centre, and., Tattersal S; Royal North Shore Hospital, Sydney, New South Wales Australia., Kiely CJ; Royal North Shore Hospital, Sydney, New South Wales Australia., Sandanayake N; Royal North Shore Hospital, Sydney, New South Wales Australia., Carlino MS; Melanoma Institute Australia.; Crown Princess Mary Cancer Centre and Westmead Hospitals, New South Wales, Australia., McCaughan G; Faculty of Medicine and Health.; Centenary Institute, The University of Sydney, Sydney, New South Wales, Australia., Wilmott JS; Melanoma Institute Australia.; Faculty of Medicine and Health.; Charles Perkins Centre, and., Scolyer RA; Melanoma Institute Australia.; Faculty of Medicine and Health.; Charles Perkins Centre, and.; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia., Long GV; Melanoma Institute Australia.; Faculty of Medicine and Health.; Royal North Shore Hospital, Sydney, New South Wales Australia.; Mater Hospital, North Sydney, New South Wales, Australia., Menzies AM; Melanoma Institute Australia.; Faculty of Medicine and Health.; Royal North Shore Hospital, Sydney, New South Wales Australia.; Mater Hospital, North Sydney, New South Wales, Australia., Palendira U; Melanoma Institute Australia.; Faculty of Medicine and Health.; Charles Perkins Centre, and.

المصدر: JCI insight [JCI Insight] 2022 Nov 08; Vol. 7 (21). Date of Electronic Publication: 2022 Nov 08.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: Electronic Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE

مواضيع طبية MeSH: Programmed Cell Death 1 Receptor* , Colitis*/chemically induced , Colitis*/therapy, Humans ; CD8-Positive T-Lymphocytes ; Immunotherapy/adverse effects ; Immunologic Factors ; Immunity, Innate

المؤلفون: Parakh S; Medical Oncology Unit, Austin Health, Melbourne, VIC, Australia.; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia., Musafer A; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia., Paessler S; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia., Witkowski T; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia., Suen CSNLW; Department of Mathematics and Statistics, La Trobe University, Melbourne, VIC, Australia., Tutuka CSA; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia., Carlino MS; Department of Medical Oncology, Westmead and Blacktown Hospitals, Sydney, NSW, Australia.; Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia., Menzies AM; Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia., Scolyer RA; Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia., Cebon J; Medical Oncology Unit, Austin Health, Melbourne, VIC, Australia.; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia., Dobrovic A; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia., Long GV; Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia.; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.; Department of Clinical Medicine, Macquarie University, Sydney, NSW, Australia., Klein O; Medical Oncology Unit, Austin Health, Melbourne, VIC, Australia.; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia., Behren A; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia.; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.

المصدر: Frontiers in immunology [Front Immunol] 2021 Jun 09; Vol. 12, pp. 672521. Date of Electronic Publication: 2021 Jun 09 (Print Publication: 2021).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

مواضيع طبية MeSH: Biomarkers, Tumor/*genetics , Drug Resistance, Neoplasm/*genetics , Immune Checkpoint Inhibitors/*therapeutic use , Melanoma/*genetics , Programmed Cell Death 1 Receptor/*genetics, Adult ; Aged ; Aged, 80 and over ; Female ; Genotype ; Humans ; Male ; Melanoma/drug therapy ; Melanoma/mortality ; Middle Aged ; Polymorphism, Single Nucleotide ; Progression-Free Survival ; Retrospective Studies

المؤلفون: Pires da Silva I; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Westmead Hospital, Sydney, NSW, Australia; Blacktown Hospital, Sydney, NSW, Australia., Ahmed T; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia., Reijers ILM; Netherlands Cancer Institute, Amsterdam, Netherlands., Weppler AM; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia., Betof Warner A; Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Patrinely JR; Vanderbilt University Medical Center, Nashville, TN, USA., Serra-Bellver P; The Christie NHS Foundation Trust, Manchester, UK., Allayous C; AP-HP Dermatology, INSERM U976, Université de Paris, Saint Louis Hospital, Paris, France., Mangana J; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland., Nguyen K; Westmead Hospital, Sydney, NSW, Australia; Blacktown Hospital, Sydney, NSW, Australia., Zimmer L; Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany., Trojaniello C; Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G Pascale, Napoli, Italy., Stout D; Alfred Hospital, Monash University, Melbourne, VIC, Australia., Lyle M; Cairns Hospital, James Cook University, Cairns, QLD, Australia., Klein O; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia., Gerard CL; Oncology Department, Lausanne University Hospital, Lausanne, Switzerland., Michielin O; Oncology Department, Lausanne University Hospital, Lausanne, Switzerland., Haydon A; Alfred Hospital, Monash University, Melbourne, VIC, Australia., Ascierto PA; Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G Pascale, Napoli, Italy., Carlino MS; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Westmead Hospital, Sydney, NSW, Australia; Blacktown Hospital, Sydney, NSW, Australia., Lebbe C; AP-HP Dermatology, INSERM U976, Université de Paris, Saint Louis Hospital, Paris, France., Lorigan P; The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK., Johnson DB; Vanderbilt University Medical Center, Nashville, TN, USA., Sandhu S; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia., Lo SN; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia., Blank CU; Netherlands Cancer Institute, Amsterdam, Netherlands., Menzies AM; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Royal North Shore Hospital, Sydney, NSW, Australia; Mater Hospital, Sydney, NSW, Australia., Long GV; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Royal North Shore Hospital, Sydney, NSW, Australia; Mater Hospital, Sydney, NSW, Australia. Electronic address: georgina.long@sydney.edu.au.

المصدر: The Lancet. Oncology [Lancet Oncol] 2021 Jun; Vol. 22 (6), pp. 836-847. Date of Electronic Publication: 2021 May 11.

نوع المنشور: Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Immune Checkpoint Inhibitors/*administration & dosage , Ipilimumab/*administration & dosage , Melanoma/*drug therapy , Programmed Cell Death 1 Receptor/*genetics, Aged ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Cohort Studies ; Drug Resistance, Neoplasm/genetics ; Drug Resistance, Neoplasm/immunology ; Female ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Ipilimumab/adverse effects ; Male ; Melanoma/genetics ; Melanoma/immunology ; Melanoma/pathology ; Middle Aged ; Neoplasm Metastasis ; Nivolumab/administration & dosage ; Nivolumab/adverse effects ; Positron Emission Tomography Computed Tomography ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Progression-Free Survival ; Retrospective Studies

المؤلفون: Patrinely JR Jr; School of Medicine, Vanderbilt University, Nashville, Tennessee., Johnson R; Melanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia.; Mater and Royal North Shore Hospitals, Sydney, New South Wales, Australia., Lawless AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston., Bhave P; Melanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia.; Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia., Sawyers A; Ronald O. Perelman Department of Dermatology, NYU Langone Health, New York University School of Medicine, New York, New York., Dimitrova M; Division of Hematology and Medical Oncology, Perlmutter Cancer Center, NYU Langone Health, New York University School of Medicine, New York, New York., Yeoh HL; Department of Medical Oncology, Alfred Health, Melbourne, Victoria, Australia., Palmeri M; Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick., Ye F; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee., Fan R; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee., Davis EJ; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Rapisuwon S; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC., Long GV; Melanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia.; Mater and Royal North Shore Hospitals, Sydney, New South Wales, Australia., Haydon A; Department of Medical Oncology, Alfred Health, Melbourne, Victoria, Australia., Osman I; Division of Hematology and Medical Oncology, Perlmutter Cancer Center, NYU Langone Health, New York University School of Medicine, New York, New York., Mehnert JM; Division of Hematology and Medical Oncology, Perlmutter Cancer Center, NYU Langone Health, New York University School of Medicine, New York, New York.; Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick., Carlino MS; Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia., Sullivan RJ; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston., Menzies AM; Melanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia.; Mater and Royal North Shore Hospitals, Sydney, New South Wales, Australia., Johnson DB; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

المصدر: JAMA oncology [JAMA Oncol] 2021 May 01; Vol. 7 (5), pp. 744-748.

نوع المنشور: Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Melanoma*/drug therapy , Melanoma*/surgery , Programmed Cell Death 1 Receptor*, Cohort Studies ; Humans ; Incidence ; Male ; Retrospective Studies

المؤلفون: Marsavela G; School of Medical and Health Sciences, Edith Cowan University, Perth, Australia., Lee J; Department of Biomedical Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia., Calapre L; School of Medical and Health Sciences, Edith Cowan University, Perth, Australia., Wong SQ; Peter MacCallum Cancer Centre, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Pereira MR; School of Medical and Health Sciences, Edith Cowan University, Perth, Australia., McEvoy AC; School of Medical and Health Sciences, Edith Cowan University, Perth, Australia., Reid AL; School of Medical and Health Sciences, Edith Cowan University, Perth, Australia., Robinson C; Anatomical Pathology, PathWest Laboratory Medicine, QEII Medical Centre, Nedlands, Australia.; School of Biomedical Science, University of Western Australia, Crawley, Australia., Warburton L; School of Medical and Health Sciences, Edith Cowan University, Perth, Australia.; Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia., Abed A; School of Medical and Health Sciences, Edith Cowan University, Perth, Australia.; Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.; Department of Medical Oncology, Fiona Stanley Hospital, Murdoch, Australia., Khattak MA; School of Medical and Health Sciences, Edith Cowan University, Perth, Australia.; Department of Medical Oncology, Fiona Stanley Hospital, Murdoch, Australia.; School of Medicine, University of Western Australia, Crawley, Australia., Meniawy TM; School of Medical and Health Sciences, Edith Cowan University, Perth, Australia.; Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.; School of Medicine, University of Western Australia, Crawley, Australia., Dawson SJ; Peter MacCallum Cancer Centre, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Sandhu S; Peter MacCallum Cancer Centre, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Carlino MS; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, New South Wales, Australia., Menzies AM; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Northern Sydney Cancer Centre, Royal North Shore Hospital, New South Wales, Australia., Scolyer RA; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.; Sydney Medical School, The University of Sydney, New South Wales, Australia.; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and New South Wales Health Pathology, New South Wales, Australia., Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Northern Sydney Cancer Centre, Royal North Shore Hospital, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.; Sydney Medical School, The University of Sydney, New South Wales, Australia., Amanuel B; School of Medical and Health Sciences, Edith Cowan University, Perth, Australia.; Anatomical Pathology, PathWest Laboratory Medicine, QEII Medical Centre, Nedlands, Australia.; School of Medicine, University of Western Australia, Crawley, Australia., Millward M; Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.; School of Medicine, University of Western Australia, Crawley, Australia., Ziman MR; School of Medical and Health Sciences, Edith Cowan University, Perth, Australia.; School of Biomedical Science, University of Western Australia, Crawley, Australia., Rizos H; Department of Biomedical Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia., Gray ES; School of Medical and Health Sciences, Edith Cowan University, Perth, Australia. e.gray@ecu.edu.au.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Nov 15; Vol. 26 (22), pp. 5926-5933. Date of Electronic Publication: 2020 Oct 16.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: CTLA-4 Antigen/*blood , Circulating Tumor DNA/*blood , Melanoma/*drug therapy , Programmed Cell Death 1 Receptor/*genetics , Proto-Oncogene Proteins B-raf/*blood, Aged ; CTLA-4 Antigen/antagonists & inhibitors ; Combined Modality Therapy/adverse effects ; Drug Therapy, Combination/methods ; Female ; Humans ; Immunotherapy/adverse effects ; MAP Kinase Kinase Kinases/genetics ; Male ; Melanoma/blood ; Melanoma/genetics ; Melanoma/immunology ; Middle Aged ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Progression-Free Survival ; Protein Kinase Inhibitors/administration & dosage

المؤلفون: Lee JH; Macquarie University, Sydney, NSW, Australia.; Melanoma Institute Australia, Sydney, NSW, Australia.; Chris O'Brien Lifehouse, Camperdown, NSW, Australia., Shklovskaya E; Macquarie University, Sydney, NSW, Australia.; Melanoma Institute Australia, Sydney, NSW, Australia., Lim SY; Macquarie University, Sydney, NSW, Australia.; Melanoma Institute Australia, Sydney, NSW, Australia., Carlino MS; Melanoma Institute Australia, Sydney, NSW, Australia.; Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Sydney, NSW, Australia., Menzies AM; Melanoma Institute Australia, Sydney, NSW, Australia.; Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, NSW, Australia., Stewart A; Macquarie University, Sydney, NSW, Australia.; Melanoma Institute Australia, Sydney, NSW, Australia., Pedersen B; Macquarie University, Sydney, NSW, Australia.; Melanoma Institute Australia, Sydney, NSW, Australia., Irvine M; Macquarie University, Sydney, NSW, Australia.; Melanoma Institute Australia, Sydney, NSW, Australia., Alavi S; Melanoma Institute Australia, Sydney, NSW, Australia.; Melanoma Oncology and Immunology, Centenary Institute, Camperdown, NSW, Australia., Yang JYH; School of Mathematics and Statistics, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia., Strbenac D; School of Mathematics and Statistics, The University of Sydney, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia., Saw RPM; Melanoma Institute Australia, Sydney, NSW, Australia.; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia., Thompson JF; Melanoma Institute Australia, Sydney, NSW, Australia.; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia., Wilmott JS; Melanoma Institute Australia, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia., Scolyer RA; Melanoma Institute Australia, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia., Long GV; Melanoma Institute Australia, Sydney, NSW, Australia.; Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia., Kefford RF; Macquarie University, Sydney, NSW, Australia.; Melanoma Institute Australia, Sydney, NSW, Australia., Rizos H; Macquarie University, Sydney, NSW, Australia. helen.rizos@mq.edu.au.; Melanoma Institute Australia, Sydney, NSW, Australia. helen.rizos@mq.edu.au.

المصدر: Nature communications [Nat Commun] 2020 Apr 20; Vol. 11 (1), pp. 1897. Date of Electronic Publication: 2020 Apr 20.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

مواضيع طبية MeSH: Cell Differentiation* , Down-Regulation* , Transcriptome*, Histocompatibility Antigens Class I/*metabolism , Melanoma/*metabolism , Programmed Cell Death 1 Receptor/*metabolism, Adult ; Aged ; Aged, 80 and over ; Cell Line, Tumor ; Drug Resistance, Neoplasm/genetics ; Female ; Gene Expression Regulation, Neoplastic ; Histocompatibility Antigens Class I/genetics ; Humans ; Immunotherapy ; Male ; Melanoma/genetics ; Melanoma/pathology ; Middle Aged ; Programmed Cell Death 1 Receptor/drug effects ; Tumor Microenvironment/drug effects

المؤلفون: Chan L; Department of Dermatology, Westmead Hospital, Sydney, Australia. Electronic address: lindachan.health@gmail.com., Hwang SJE; Department of Dermatology, Westmead Hospital, Sydney, Australia; Sydney Medical School, The University of Sydney, Westmead, Australia., Byth K; Research and Education Network, Western Sydney Local Health District, Westmead Hospital, Westmead, Australia; NHMRC Clinical Trials Centre, Sydney Medical School, The University of Sydney, Sydney, Australia., Kyaw M; Department of Radiology, Westmead Hospital, Sydney, Australia., Carlino MS; Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Sydney, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia., Chou S; Tissue Pathology and Diagnostic Oncology, Westmead Hospital, Sydney, Australia., Fernandez-Penas P; Department of Dermatology, Westmead Hospital, Sydney, Australia; Sydney Medical School, The University of Sydney, Westmead, Australia.

المصدر: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2020 Feb; Vol. 82 (2), pp. 311-316. Date of Electronic Publication: 2019 Jun 21.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents, Immunological/*therapeutic use , Melanoma/*drug therapy , Programmed Cell Death 1 Receptor/*antagonists & inhibitors , Skin/*drug effects , Skin Neoplasms/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Immunological/pharmacology ; Australia/epidemiology ; Eczema/chemically induced ; Eczema/epidemiology ; Eczema/immunology ; Female ; Follow-Up Studies ; Humans ; Hypopigmentation/chemically induced ; Hypopigmentation/epidemiology ; Hypopigmentation/immunology ; Incidence ; Lichenoid Eruptions/chemically induced ; Lichenoid Eruptions/epidemiology ; Lichenoid Eruptions/immunology ; Male ; Melanoma/immunology ; Melanoma/mortality ; Middle Aged ; Prognosis ; Programmed Cell Death 1 Receptor/immunology ; Progression-Free Survival ; Prospective Studies ; Skin/immunology ; Skin Neoplasms/immunology ; Skin Neoplasms/mortality ; Young Adult

المؤلفون: Pires da Silva I; Melanoma Institute Australia, Sydney, New South Wales, Australia.; Central Clinical School, The University of Sydney, Sydney, New South Wales, Australia., Lo S; Melanoma Institute Australia, Sydney, New South Wales, Australia.; Central Clinical School, The University of Sydney, Sydney, New South Wales, Australia., Quek C; Melanoma Institute Australia, Sydney, New South Wales, Australia.; Central Clinical School, The University of Sydney, Sydney, New South Wales, Australia., Gonzalez M; Melanoma Institute Australia, Sydney, New South Wales, Australia., Carlino MS; Melanoma Institute Australia, Sydney, New South Wales, Australia.; Western Clinical School, The University of Sydney, Sydney, New South Wales, Australia.; Department of Medical Oncology, Westmead and Blacktown Hospitals, Sydney, New South Wales, Australia., Long GV; Melanoma Institute Australia, Sydney, New South Wales, Australia.; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.; Northern Clinical School, The University of Sydney, Sydney, New South Wales, Australia., Menzies AM; Melanoma Institute Australia, Sydney, New South Wales, Australia.; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.; Northern Clinical School, The University of Sydney, Sydney, New South Wales, Australia.

المصدر: Cancer [Cancer] 2020 Jan 01; Vol. 126 (1), pp. 86-97. Date of Electronic Publication: 2019 Oct 04.

نوع المنشور: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents, Immunological/*administration & dosage , Ipilimumab/*administration & dosage , Melanoma/*drug therapy , Programmed Cell Death 1 Receptor/*antagonists & inhibitors, Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Disease Progression ; Female ; Humans ; Ipilimumab/adverse effects ; Male ; Melanoma/immunology ; Melanoma/pathology ; Middle Aged ; Neoplasm Metastasis ; Nivolumab/administration & dosage ; Nivolumab/adverse effects ; Programmed Cell Death 1 Receptor/immunology ; Progression-Free Survival

المؤلفون: Gide TN; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, Australia.; Sydney Medical School, The University of Sydney, Sydney, Australia., Silva IP; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, Australia.; Sydney Medical School, The University of Sydney, Sydney, Australia., Quek C; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, Australia.; Sydney Medical School, The University of Sydney, Sydney, Australia., Ahmed T; Melanoma Institute Australia, The University of Sydney, Sydney, Australia., Menzies AM; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, Australia.; Sydney Medical School, The University of Sydney, Sydney, Australia.; Royal North Shore Hospital, Sydney, Australia.; Mater Hospital, North Sydney, Australia., Carlino MS; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.; Sydney Medical School, The University of Sydney, Sydney, Australia.; Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Sydney, Australia., Saw RPM; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.; Sydney Medical School, The University of Sydney, Sydney, Australia.; Royal Prince Alfred Hospital, Sydney, Australia.; Mater Hospital, North Sydney, Australia., Thompson JF; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.; Sydney Medical School, The University of Sydney, Sydney, Australia.; Royal Prince Alfred Hospital, Sydney, Australia.; Mater Hospital, North Sydney, Australia., Batten M; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, Australia.; Sydney Medical School, The University of Sydney, Sydney, Australia., Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, Australia.; Sydney Medical School, The University of Sydney, Sydney, Australia.; Royal North Shore Hospital, Sydney, Australia.; Mater Hospital, North Sydney, Australia., Scolyer RA; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, Australia.; Sydney Medical School, The University of Sydney, Sydney, Australia.; Royal Prince Alfred Hospital, Sydney, Australia., Wilmott JS; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, Australia.; Sydney Medical School, The University of Sydney, Sydney, Australia.

المصدر: Oncoimmunology [Oncoimmunology] 2019 Oct 16; Vol. 9 (1), pp. 1659093. Date of Electronic Publication: 2019 Oct 16 (Print Publication: 2020).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Print ISSN: 2162-4011 (Print) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology

مواضيع طبية MeSH: Melanoma*/drug therapy , Programmed Cell Death 1 Receptor*, Humans ; Immunotherapy ; Ipilimumab ; Lymphocytes, Tumor-Infiltrating